罗格列酮相关心血管事件概述

被引:4
作者
王梦然 [1 ]
李敏 [1 ]
机构
[1] 首都医科大学附属北京友谊医院综合科
关键词
罗格列酮; 心血管事件; 不良反应;
D O I
暂无
中图分类号
R977.15 [];
学科分类号
1007 ;
摘要
罗格列酮为噻唑烷二酮类口服降糖药,能改善胰岛素敏感性,用于治疗2型糖尿病。近年,罗格列酮的心血管风险受到人们关注。一项荟萃分析显示:罗格列酮组与对照组比较,心肌梗死的优势比(OR)为1.43,[95%可信区间(CI)1.03~1.98,P=0.03];心血管性死亡OR为1.64,(95%CI0.98~2.74,P=0.06),表明罗格列酮与心肌梗死及心血管性死亡有关联。然而,最近RECORD中期研究显示:罗格列酮组心肌梗死49例,对照组40例(P=0.34),而两组的充血性心力衰竭分别为47例和22例(P=0.003),表明罗格列酮不增加心肌梗死和心血管性死亡风险,但可使充血性心力衰竭风险增加。另外,FDA2008年发布了有关罗格列酮的用药指南和处方信息,罗格列酮禁用于严重心力衰竭患者。因此,使用罗格列酮时应权衡利弊,并应个体化用药。
引用
收藏
页码:31 / 34
页数:4
相关论文
共 18 条
[11]  
Thiazolidinediones ex-pand body fluid volume via PPARγ?Stimulation of ENaC-me-diated renal sodium absorption. Guan Y,Hao CM,Breyer MD,et al. Nature Medicine . 2005
[12]  
Collecting duct-specific deletion of peroxisome proliferator-activated receptor {gamma} blocks thiazolidinedione-induced fluid retention. Zhang,H,Zhang,A,Kohan,DE,Nelson,RD,Gonzalez,FJ,Yang,T. Proceedings of the National Academy of Sciences of the United States of America . 2005
[13]  
Kidney and glitazones. Deray G,Izzedine H,Launay-Vacher Vet al. Annales d Endocrinologie . 2005
[14]  
Rosiglitazone ev-aluated for cardiovascular outcomes-an Interim anal-ysis. Home PD,Pocock SJ,Beck NH,et al. The New England Journal of Medicine . 2007
[15]  
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. Nissen,SE,Wolski,K. The New England Journal of Medicine . 2007
[16]  
Highlights of prescribing information:Avandia(ro-siglitazone maleate)tablets. FDA. http://www.fda.gov/cder/foi/label/2008/02107ls0291b1.pdf . 2008
[17]  
FDA and GlaxoSmithKline notified pharmacists and physicians of a new Medication Giude for Avandia(rosig-litazone maleate). FDA. http://www.fda.gov/medw Atch/safety/2008/safety08.htm#Avan-dia . 2008
[18]  
Comparison of car-diovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Winkelmayer WC,,Setoguchi S,et al. Archives of Internal Medicine . 2008